Division of Nephrology, Centre Hospitalier de l'Université de Montréal, Montréal, Canada.
Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.
Nephrol Dial Transplant. 2021 Sep 27;36(10):1937-1946. doi: 10.1093/ndt/gfaa159.
In the era of organ shortage, home hemodialysis (HHD) has been identified as the possible preferential bridge to kidney transplantation. Data are conflicting regarding the comparability of HHD and transplantation outcomes. This study aimed to compare patient and treatment survival between HHD patients and kidney transplant recipients.
The Australia and New Zealand Dialysis and Transplant Registry was used to include incident HHD patients on Day 90 after initiation of kidney replacement therapy and first kidney-only transplant recipients in Australia and New Zealand from 1997 to 2017. Survival times were analyzed using the Kaplan-Meier product-limit method comparing HHD patients with subtypes of kidney transplant recipients using the log-rank test. Adjusted analyses were performed with multivariable Cox proportional hazards regression models for time to all-cause mortality. Time-to-treatment failure or death was assessed as a composite secondary outcome.
The study compared 1411 HHD patients with 4960 living donor (LD) recipients, 6019 standard criteria donor (SCD) recipients and 2427 expanded criteria donor (ECD) recipients. While LD and SCD recipients had reduced risks of mortality compared with HHD patients [LD adjusted hazard ratio (HR) = 0.57, 95% confidence interval (CI) 0.46-0.71; SCD HR = 0.65 95% CI 0.52-0.79], the risk of mortality was comparable between ECD recipients and HHD patients (HR = 0.90, 95% CI 0.73-1.12). LD, SCD and ECD kidney recipients each experienced superior time-to-treatment failure or death compared with HHD patients.
This large registry study showed that kidney transplant offers a survival benefit compared with HHD but that this advantage is not significant for ECD recipients.
在器官短缺的时代,家庭血液透析(HHD)已被确定为可能的优先移植桥梁。关于 HHD 和移植结局的可比性,数据存在争议。本研究旨在比较 HHD 患者和肾移植受者的患者和治疗存活率。
使用澳大利亚和新西兰透析和移植登记处,纳入 1997 年至 2017 年期间澳大利亚和新西兰开始肾脏替代治疗后第 90 天的 HHD 患者和首次肾单一移植受者。使用 Kaplan-Meier 乘积限法分析生存时间,通过对数秩检验比较 HHD 患者与不同类型肾移植受者的生存时间。使用多变量 Cox 比例风险回归模型对全因死亡率进行调整分析。将治疗失败或死亡的时间评估为复合次要结局。
该研究比较了 1411 例 HHD 患者与 4960 例活体供体(LD)受者、6019 例标准标准供体(SCD)受者和 2427 例扩展标准供体(ECD)受者。与 HHD 患者相比,LD 和 SCD 受者的死亡风险降低[LD 调整后的风险比(HR)=0.57,95%置信区间(CI)0.46-0.71;SCD HR = 0.65,95% CI 0.52-0.79],但 ECD 受者与 HHD 患者的死亡风险相当(HR = 0.90,95% CI 0.73-1.12)。LD、SCD 和 ECD 肾受者的治疗失败或死亡时间均优于 HHD 患者。
这项大型登记研究表明,与 HHD 相比,肾移植具有生存优势,但这一优势对 ECD 受者并不显著。